• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过乳腺癌细胞系染色质可及性分析鉴定谱系特异性表观遗传调控因子 FOXA1 和 GRHL2。

Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.

机构信息

Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.

出版信息

Cancer Gene Ther. 2024 May;31(5):736-745. doi: 10.1038/s41417-024-00745-z. Epub 2024 Mar 1.

DOI:10.1038/s41417-024-00745-z
PMID:38429368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11101334/
Abstract

Breast cancer is a heterogeneous disease, and breast cancer cell lines are invaluable for studying this heterogeneity. However, the epigenetic diversity across these cell lines remains poorly understood. In this study, we performed genome-wide chromatin accessibility analysis on 23 breast cancer cell lines, including 2 estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-), 3 ER+/HER2+, 3 HER2+, and 15 triple-negative breast cancer (TNBC) lines. These cell lines were classified into three groups based on their chromatin accessibility: the receptor-positive group (Group-P), TNBC basal group (Group-B), and TNBC mesenchymal group (Group-M). Motif enrichment analysis revealed that only Group-P exhibited coenrichment of forkhead box A1 (FOXA1) and grainyhead-like 2 (GRHL2) motifs, whereas Group-B was characterized by the presence of the GRHL2 motif without FOXA1. Notably, Group-M did not show enrichment of either FOXA1 or GRHL2 motifs. Furthermore, gene ontology analysis suggested that group-specific accessible regions were associated with their unique lineage characteristics. To investigate the epigenetic landscape regulatory roles of FOXA1 and GRHL2, we performed knockdown experiments targeting FOXA1 and GRHL2, followed by assay for transposase-accessible chromatin sequencing analysis. The findings revealed that FOXA1 maintains Group-P-specific regions while suppressing Group-B-specific regions in Group-P cells. In contrast, GRHL2 preserves commonly accessible regions shared between Group-P and Group-B in Group-B cells, suggesting that FOXA1 and GRHL2 play a pivotal role in preserving distinct chromatin accessibility patterns for each group. Specifically, FOXA1 distinguishes between receptor-positive and TNBC cell lines, whereas GRHL2 distinguishes between basal-like and mesenchymal subtypes in TNBC lines.

摘要

乳腺癌是一种异质性疾病,乳腺癌细胞系对于研究这种异质性非常有价值。然而,这些细胞系之间的表观遗传多样性仍了解甚少。在这项研究中,我们对 23 种乳腺癌细胞系进行了全基因组染色质可及性分析,包括 2 种雌激素受体(ER)阳性/人表皮生长因子受体 2(HER2)阴性(ER+/HER2-)、3 种 ER+/HER2+、3 种 HER2+和 15 种三阴性乳腺癌(TNBC)细胞系。这些细胞系根据染色质可及性分为三组:受体阳性组(Group-P)、TNBC 基底组(Group-B)和 TNBC 间质组(Group-M)。基序富集分析显示,只有 Group-P 表现出叉头框 A1(FOXA1)和粒状头样 2(GRHL2)基序的共富集,而 Group-B 的特征是存在 GRHL2 基序而没有 FOXA1。值得注意的是,Group-M 既没有 FOXA1 也没有 GRHL2 基序的富集。此外,基因本体分析表明,特定组的可及区域与它们独特的谱系特征有关。为了研究 FOXA1 和 GRHL2 的表观遗传景观调节作用,我们针对 FOXA1 和 GRHL2 进行了敲低实验,随后进行了转座酶可及染色质测序分析。结果表明,FOXA1 在 Group-P 细胞中维持 Group-P 特异性区域,同时抑制 Group-B 特异性区域。相反,GRHL2 在 Group-B 细胞中保留了 Group-P 和 Group-B 之间共同可及的区域,这表明 FOXA1 和 GRHL2 在维持每个组的独特染色质可及性模式方面发挥着关键作用。具体来说,FOXA1 区分受体阳性和 TNBC 细胞系,而 GRHL2 区分 TNBC 细胞系中的基底样和间质亚型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/ef0da7ceba88/41417_2024_745_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/dc2e984808b8/41417_2024_745_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/412988ad361c/41417_2024_745_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/49a9c969017e/41417_2024_745_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/626cbca979b3/41417_2024_745_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/ef0da7ceba88/41417_2024_745_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/dc2e984808b8/41417_2024_745_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/412988ad361c/41417_2024_745_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/49a9c969017e/41417_2024_745_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/626cbca979b3/41417_2024_745_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ec6/11101334/ef0da7ceba88/41417_2024_745_Fig5_HTML.jpg

相似文献

1
Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.通过乳腺癌细胞系染色质可及性分析鉴定谱系特异性表观遗传调控因子 FOXA1 和 GRHL2。
Cancer Gene Ther. 2024 May;31(5):736-745. doi: 10.1038/s41417-024-00745-z. Epub 2024 Mar 1.
2
Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights into methylation patterns and chromatin accessibility dynamics.探讨 ID4 在乳腺癌中的表观遗传学特征:甲基化模式和染色质可及性动态的生物信息学见解。
Breast Cancer Res Treat. 2024 Aug;207(1):91-101. doi: 10.1007/s10549-024-07343-5. Epub 2024 May 3.
3
Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.雄激素受体和 FOXA1 的共表达定义了一种“腔面雄激素受体”的猫乳腺肿瘤亚型,这是乳腺癌的自发模型。
BMC Cancer. 2019 Dec 30;19(1):1267. doi: 10.1186/s12885-019-6483-6.
4
Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.驱动人尿路上皮基底细胞和管腔细胞表型的转录因子层级结构。
Cell Death Differ. 2017 May;24(5):809-818. doi: 10.1038/cdd.2017.10. Epub 2017 Mar 10.
5
FOXA1 represses the molecular phenotype of basal breast cancer cells.FOXA1 抑制基底型乳腺癌细胞的分子表型。
Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.
6
FOXA1 is a key determinant of estrogen receptor function and endocrine response.FOXA1 是雌激素受体功能和内分泌反应的关键决定因素。
Nat Genet. 2011 Jan;43(1):27-33. doi: 10.1038/ng.730. Epub 2010 Dec 12.
7
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.FOXA1 突变揭示了不同的染色质特征,并影响乳腺癌的治疗反应。
Cancer Cell. 2020 Oct 12;38(4):534-550.e9. doi: 10.1016/j.ccell.2020.08.003. Epub 2020 Sep 3.
8
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer.转录因子 Grainyhead-like 2(GRHL2)在乳腺癌中的双重作用。
J Biol Chem. 2013 Aug 9;288(32):22993-3008. doi: 10.1074/jbc.M113.456293. Epub 2013 Jun 29.
9
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer.GRHL2基序与管腔型乳腺癌中顺式调控元件的肿瘤内异质性相关。
NPJ Breast Cancer. 2022 Jun 8;8(1):70. doi: 10.1038/s41523-022-00438-6.
10
Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.叉头框蛋白A1(FOXA1)的下调通过诱导白细胞介素-6导致他莫昔芬耐药乳腺癌细胞具有癌症干细胞样特性。
J Biol Chem. 2017 May 19;292(20):8136-8148. doi: 10.1074/jbc.M116.763276. Epub 2017 Mar 7.

引用本文的文献

1
Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application.染色质可及性:生物学功能、分子机制及治疗应用
Signal Transduct Target Ther. 2024 Dec 4;9(1):340. doi: 10.1038/s41392-024-02030-9.
2
Conserved role of FOXC1 in TNBC is parallel to FOXA1 in ER+ breast cancer.FOXC1在三阴性乳腺癌中的保守作用与FOXA1在雌激素受体阳性乳腺癌中的作用相似。
iScience. 2024 Jul 14;27(8):110500. doi: 10.1016/j.isci.2024.110500. eCollection 2024 Aug 16.
3
EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.

本文引用的文献

1
Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.基于染色质构象分析鉴定新型雌激素受体阳性乳腺癌亚组,该亚组雌激素反应元件的可及性降低。
Br J Cancer. 2023 Mar;128(7):1208-1222. doi: 10.1038/s41416-023-02178-1. Epub 2023 Feb 1.
2
GRHL2 Enhances Phosphorylated Estrogen Receptor (ER) Chromatin Binding and Regulates ER-Mediated Transcriptional Activation and Repression.GRHL2 增强磷酸化雌激素受体(ER)染色质结合,并调节 ER 介导的转录激活和抑制。
Mol Cell Biol. 2022 Oct 20;42(10):e0019122. doi: 10.1128/mcb.00191-22. Epub 2022 Aug 29.
3
EZH2 PROTACs 靶向 EZH2 和 FOXM1 相关的致癌节点,抑制乳腺癌细胞生长。
Oncogene. 2024 Aug;43(36):2722-2736. doi: 10.1038/s41388-024-03119-9. Epub 2024 Aug 7.
Chromatin structure in cancer.
染色质结构与癌症。
BMC Mol Cell Biol. 2022 Jul 28;23(1):35. doi: 10.1186/s12860-022-00433-6.
4
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer.GRHL2基序与管腔型乳腺癌中顺式调控元件的肿瘤内异质性相关。
NPJ Breast Cancer. 2022 Jun 8;8(1):70. doi: 10.1038/s41523-022-00438-6.
5
A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response.单细胞分析乳腺癌细胞系以研究肿瘤异质性和药物反应。
Nat Commun. 2022 Mar 31;13(1):1714. doi: 10.1038/s41467-022-29358-6.
6
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?HR 阳性/HER2 阴性早期乳腺癌的风险分层精细化:如何选择需要强化治疗的患者?
Breast Cancer Res Treat. 2022 Apr;192(3):465-484. doi: 10.1007/s10549-022-06535-1. Epub 2022 Feb 6.
7
Integrative epigenomic profiling reveal AP-1 is a key regulator in intrahepatich cholangiocarcinoma.综合表观基因组分析揭示AP-1是肝内胆管癌的关键调节因子。
Genomics. 2022 Jan;114(1):241-252. doi: 10.1016/j.ygeno.2021.12.008. Epub 2021 Dec 20.
8
E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer.E2A 调节乳腺癌的干性、转移和治疗抵抗。
Cancer Res. 2021 Sep 1;81(17):4529-4544. doi: 10.1158/0008-5472.CAN-20-2685. Epub 2021 Jun 18.
9
Long noncoding RNAs in cancer metastasis.长非编码 RNA 在癌症转移中的作用。
Nat Rev Cancer. 2021 Jul;21(7):446-460. doi: 10.1038/s41568-021-00353-1. Epub 2021 May 5.
10
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.FOXA1 突变揭示了不同的染色质特征,并影响乳腺癌的治疗反应。
Cancer Cell. 2020 Oct 12;38(4):534-550.e9. doi: 10.1016/j.ccell.2020.08.003. Epub 2020 Sep 3.